Fulvestrant

Hangzhou Hysen Pharma, based in Hangzhou, Zhejiang, supplies Fulvestrant for oncology applications. The listing states the material is produced under stringent quality controls and meets a high purity level. It is offered in bulk quantities suitable for hospitals, clinics and pharmaceutical manufacturers. The product complies with international pharmaceutical standards as indicated by the supplier.

Fulvestrant is an estrogen receptor antagonist used to treat hormone‑receptor‑positive breast cancer in post‑menopausal women. In the market the drug is commonly formulated as an injectable solution for intramuscular administration. Typical industry grades contain ≥ 99 % active ingredient with standard excipients such as benzyl alcohol and polysorbate 80. The supplier notes that the product is packaged in sealed glass vials and protected for transport.

Buyers normally require documentation of assay, purity and sterility before release. Shipping options include L/C and T/T with the possibility of containerised transport under temperature‑controlled conditions. The supplier’s trust tier is listed as “harbor” and the response rate is currently zero, so direct confirmation of MOQ and lead time is advised. Importers should align payment and Incoterm terms with the supplier’s capabilities before finalising the order.

Hangzhou Hysen Pharma is located on Gudun Road in Hangzhou, Zhejiang, China (postal code 310012). The company is classified as an imported supplier and carries a trust tier of “harbor”. Its profile does not include a recorded response rate, showing a current value of 0 % and an average response time of zero hours. The listing does not provide additional corporate history beyond the address and verification signals.

The supplier offers Fulvestrant in bulk quantities for institutional buyers. No specific information on annual production capacity or employee count is disclosed. Potential buyers should verify the supplier’s current certifications and quality management system directly. Communication channels and negotiation terms are to be established through the supplier’s own contact points.